A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors



Status:Recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:12 - Any
Updated:1/25/2019
Start Date:July 2, 2018
End Date:October 9, 2020
Contact:Trial Transparency email recommended (Toll free number for US & Canada)
Email:Contact-US@sanofi.com
Phone:800-633-1610

Use our guide to learn which trials are right for you!

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

The purpose of this study is to determine the frequency of bleeding episodes in patients
receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are
assigned to continue with their regular medication. In addition, the study will assess
safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).


Inclusion Criteria:

- Males, ≥12 years of age

- Severe hemophilia A or B without inhibitors

- (Severity confirmed by a central laboratory where FVIII level is <1% or FIX level
is ≤2% at Screening; Inhibitors defined as Nijmegen modified Bethesda assay
inhibitor titer of <0.6 BU/mL at Screening)

- A minimum of 6 bleeding episodes requiring factor concentrate treatment within the
last 6 months prior to Screening.

- Willing and able to comply with the study requirements and to provide written informed
consent and assent

Exclusion Criteria:

- Known co-existing bleeding disorders other than hemophilia A or B

- Antithrombin (AT) activity <60% at Screening

- Co-existing thrombophilic disorder

- Clinically significant liver disease

- Active HCV infection

- HIV positive with a CD4 count of <200 cells/μL

- History of arterial or venous thromboembolism

- Inadequate renal function

- History of multiple drug allergies or history of allergic reaction to an
oligonucleotide or N-Acetylgalactosamine (GalNAc)

- History of intolerance to SC injection(s)

- Any other conditions or comorbidities that would make the patient unsuitable for
enrollment or could interfere with participation in or completion of the study, per
Investigator judgment
We found this trial at
11
sites
89 Commercial Road
Melbourne, 3004
?
mi
from
Melbourne,
Click here to add this to my saved trials
530 South Main Street
Akron, Ohio 44311
?
mi
from
Akron, OH
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Boston, Massachusetts 02114
?
mi
from
Boston, MA
Click here to add this to my saved trials
6330 Quadrangle Drive
Chapel Hill, North Carolina 27517
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cleveland, Ohio 44195
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Las Vegas, Nevada 89109
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Orange, California
?
mi
from
Orange, CA
Click here to add this to my saved trials
Phoenix, Arizona 85016
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
San Diego, California
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Tampa, Florida
?
mi
from
Tampa, FL
Click here to add this to my saved trials